Foundayo 9 MG Oral Tablet

RxCUI: 2739862
RxNorm name: Foundayo 9 MG Oral Tablet
Display name: Foundayo 9 MG Oral Tablet
Full name: Foundayo 9 MG Oral Tablet
Term type: PSN
Status: DailyMed mapping
Updated: 2026-06-04 23:39:07

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
FOUNDAYO	ORFORGLIPRON	Eli Lilly and Company	8ac446c5-feba-474f-a103-23facb9b5c62	2026-07-29	Boxed warning, Warnings, Adverse reactions	Exact identifier rxcui: 2739862

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set ID	RxNorm mappings	Terms	SPL version	Label	Effective
8ac446c5-feba-474f-a103-23facb9b5c62	Foundayo 9 MG Oral Tablet [PSN] · orforglipron 9 MG Oral Tablet [Foundayo] [SBD] · Foundayo 9 MG (equivalent to orforglipron calcium 9.194 MG) Oral Tablet [SY]	3	5	These highlights do not include all the information needed to use FOUNDAYO safely and effectively. See full prescribing information for FOUNDAYO. FOUNDAYO (orforglipron) tablets, for oral use Initial U.S. Approval: 2026	20260401